Rapport Therapeutics Inc.
XNAS:RAPP 4:00:00 PM EDT
| Market Cap (Intraday) | 1.85B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $36.81 |
| 50-Day MA | $34.05 |
| 200-Day MA | $27.97 |
Rapport Therapeutics Inc. Stock, XNAS:RAPP
1325 Boylston Street, Suite 401, Boston, Massachusetts 02215
United States of America
Phone: +1.857.321.8020
Number of Employees: 69
Description
Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.